» Articles » PMID: 22814311

Reproducibility of Histopathological Subtypes and Invasion in Pulmonary Adenocarcinoma. An International Interobserver Study

Abstract

Histological subtyping of pulmonary adenocarcinoma has recently been updated based on predominant pattern, but data on reproducibility are required for validation. This study first assesses reproducibility in subtyping adenocarcinomas and then assesses further the distinction between invasive and non-invasive (wholly lepidic) pattern of adenocarcinoma, among an international group of pulmonary pathologists. Two ring studies were performed using a micro-photographic image-based method, evaluating selected images of lung adenocarcinoma histologic patterns. In the first study, 26 pathologists reviewed representative images of typical and 'difficult' histologic patterns. A total number of scores for the typical patterns combined (n=94) and the difficult cases (n=21) were 2444 and 546, respectively. The mean kappa score (±s.d.) for the five typical patterns combined and for difficult cases were 0.77±0.07 and 0.38±0.14, respectively. Although 70% of the observers identified 12-65% of typical images as single pattern, highest for solid and least for micropapillary, recognizing the predominant pattern was achieved in 92-100%, of the images except for micropapillary pattern (62%). For the second study on invasion, identified as a key problem area from the first study, 28 pathologists submitted and reviewed 64 images representing typical as well as 'difficult' examples. The kappa for typical and difficult cases was 0.55±0.06 and 0.08±0.02, respectively, with consistent subdivision by the same pathologists into invasive and non-invasive categories, due to differing interpretation of terminology defining invasion. In pulmonary adenocarcinomas with classic morphology, which comprise the majority of cases, there is good reproducibility in identifying a predominant pattern and fair reproducibility distinguishing invasive from in-situ (wholly lepidic) patterns. However, more precise definitions and better education on interpretation of existing terminology are required to improve recognition of purely in-situ disease, this being an area of increasing importance.

Citing Articles

Impact of histopathological subtypes on invasive lung adenocarcinoma: from epidemiology to tumour microenvironment to therapeutic strategies.

Xin S, Wen M, Tian Y, Dong H, Wan Z, Jiang S World J Surg Oncol. 2025; 23(1):66.

PMID: 40016762 PMC: 11866629. DOI: 10.1186/s12957-025-03701-9.


Identifying invasiveness to aid lung adenocarcinoma diagnosis using deep learning and pathomics.

Du H, Wang X, Wang K, Ai Q, Shen J, Zhu R Sci Rep. 2025; 15(1):4913.

PMID: 39929860 PMC: 11810995. DOI: 10.1038/s41598-025-87094-5.


Autofluorescence Virtual Staining System for H&E Histology and Multiplex Immunofluorescence Applied to Immuno-Oncology Biomarkers in Lung Cancer.

Loo J, Robbins M, McNeil C, Yoshitake T, Santori C, Shan C Cancer Res Commun. 2024; 5(1):54-65.

PMID: 39636222 PMC: 11707747. DOI: 10.1158/2767-9764.CRC-24-0327.


Reproducibility of Assessment of Lepidic (Noninvasive) Patterns in Lung Adenocarcinoma With Cytokeratin Immunostain Compared With Hematoxylin and Eosin and the Proposed New International Association for the Study of Lung Cancer (IASLC) Algorithm.

Yang E, Alshamlan N, Hueniken K, Weiss J, Cabanero M, Tsao M JTO Clin Res Rep. 2024; 5(7):100682.

PMID: 39100653 PMC: 11294719. DOI: 10.1016/j.jtocrr.2024.100682.


Mapping the landscape of histomorphological cancer phenotypes using self-supervised learning on unannotated pathology slides.

Claudio Quiros A, Coudray N, Yeaton A, Yang X, Liu B, Le H Nat Commun. 2024; 15(1):4596.

PMID: 38862472 PMC: 11525555. DOI: 10.1038/s41467-024-48666-7.


References
1.
Dale I, LEXOW P, SKJORTEN F, Stenwig J, Brandtzaeg P . Reproducibility of tumour typing of lung carcinomas performed according to WHO's recommendation. APMIS. 1989; 97(4):351-6. DOI: 10.1111/j.1699-0463.1989.tb00799.x. View

2.
Thunnissen F, Kerr K, Brambilla E, Comin C, Franklin W, Guldhammerskov B . EU-USA pathology panel for uniform diagnosis in randomised controlled trials for HRCT screening in lung cancer. Eur Respir J. 2006; 28(6):1186-9. DOI: 10.1183/09031936.06.00043506. View

3.
Stang A, Pohlabeln H, Muller K, Jahn I, Giersiepen K, Jockel K . Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006; 52(1):29-36. DOI: 10.1016/j.lungcan.2005.11.012. View

4.
Russell P, Wainer Z, Wright G, Daniels M, Conron M, Williams R . Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung.... J Thorac Oncol. 2011; 6(9):1496-504. DOI: 10.1097/JTO.0b013e318221f701. View

5.
Noguchi M, Minami Y, Iijima T, Matsuno Y . Reproducibility of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteria. Pathol Int. 2005; 55(1):8-13. DOI: 10.1111/j.1440-1827.2005.01782.x. View